Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Proteomic profiling of N-linked glycoproteins identifies ConA-binding procathepsin D as a novel serum biomarker for hepatocellular carcinoma.

Qi YJ, Ward DG, Pang C, Wang QM, Wei W, Ma J, Zhang J, Lou Q, Shimwell NJ, Martin A, Wong N, Chao WX, Wang M, Ma YF, Johnson PJ.

Proteomics. 2014 Feb;14(2-3):186-95. doi: 10.1002/pmic.201300226.

PMID:
24259486
2.

Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach.

Ang IL, Poon TC, Lai PB, Chan AT, Ngai SM, Hui AY, Johnson PJ, Sung JJ.

J Proteome Res. 2006 Oct;5(10):2691-700.

PMID:
17022640
3.

Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma.

Na K, Lee EY, Lee HJ, Kim KY, Lee H, Jeong SK, Jeong AS, Cho SY, Kim SA, Song SY, Kim KS, Cho SW, Kim H, Paik YK.

Proteomics. 2009 Aug;9(16):3989-99. doi: 10.1002/pmic.200900105.

PMID:
19658107
4.

Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach.

Qiao B, Wang J, Xie J, Niu Y, Ye S, Wan Q, Ye Q.

Int J Mol Med. 2012 May;29(5):832-40. doi: 10.3892/ijmm.2012.916. Epub 2012 Feb 15.

PMID:
22344546
5.

Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.

Lee MJ, Yu GR, Park SH, Cho BH, Ahn JS, Park HJ, Song EY, Kim DG.

Clin Cancer Res. 2008 Feb 15;14(4):1080-9. doi: 10.1158/1078-0432.CCR-07-1615.

6.

Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma.

Junrong T, Huancheng Z, Feng H, Yi G, Xiaoqin Y, Zhengmao L, Hong Z, Jianying Z, Yin W, Yuanhang H, Jianlin Z, Longhua S, Guolin H.

J Biosci. 2011 Sep;36(4):659-68.

7.

Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm).

Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ, Luk JM.

J Proteome Res. 2010 Apr 5;9(4):1923-30. doi: 10.1021/pr901085z.

PMID:
20121168
9.

Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients.

Sun C, Chen P, Chen Q, Sun L, Kang X, Qin X, Liu Y.

Acta Biochim Biophys Sin (Shanghai). 2012 Sep;44(9):765-73. doi: 10.1093/abbs/gms055. Epub 2012 Jul 1.

PMID:
22751611
10.

TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis.

Wang Y, He D, Yang L, Wen B, Dai J, Zhang Q, Kang J, He W, Ding Q, He D.

Biochem Biophys Res Commun. 2015 Jul 31;463(3):458-65. doi: 10.1016/j.bbrc.2015.05.117. Epub 2015 Jun 1.

PMID:
26043685
11.

Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma.

Chen R, Tan Y, Wang M, Wang F, Yao Z, Dong L, Ye M, Wang H, Zou H.

Mol Cell Proteomics. 2011 Jul;10(7):M110.006445. doi: 10.1074/mcp.M110.006445. Epub 2011 Apr 7.

12.

Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma.

Huang C, Wang Y, Liu S, Ding G, Liu W, Zhou J, Kuang M, Ji Y, Kondo T, Fan J.

J Proteome Res. 2013 Apr 5;12(4):1838-46. doi: 10.1021/pr3011815. Epub 2013 Mar 5.

PMID:
23442176
13.

High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques.

Qin X, Chen Q, Sun C, Wang C, Peng Q, Xie L, Liu Y, Li S.

Med Oncol. 2013 Mar;30(1):420. doi: 10.1007/s12032-012-0420-8. Epub 2013 Jan 6.

PMID:
23292873
14.

Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.

He QY, Zhu R, Lei T, Ng MY, Luk JM, Sham P, Lau GK, Chiu JF.

J Cell Biochem. 2008 Feb 15;103(3):740-52.

PMID:
17557278
15.

Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.

Long J, Lang ZW, Wang HG, Wang TL, Wang BE, Liu SQ.

Hepatobiliary Pancreat Dis Int. 2010 Jun;9(3):296-305.

16.

Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples.

Wang C, Guo K, Gao D, Kang X, Jiang K, Li Y, Sun L, Zhang S, Sun C, Liu X, Wu W, Yang P, Liu Y.

Cancer Lett. 2011 Dec 27;313(2):154-66. doi: 10.1016/j.canlet.2011.08.031. Epub 2011 Oct 8.

PMID:
22023829
17.

Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to α fetoprotein.

Shu H, Kang X, Guo K, Li S, Li M, Sun L, Gan L, Liu Y, Qin X.

Oncol Rep. 2010 Nov;24(5):1271-6.

PMID:
20878120
18.

GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population.

Hu JS, Wu DW, Liang S, Miao XY.

Med Oncol. 2010 Jun;27(2):339-45. doi: 10.1007/s12032-009-9215-y. Epub 2009 Apr 28.

PMID:
19399652
19.
20.

Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.

Orimo T, Ojima H, Hiraoka N, Saito S, Kosuge T, Kakisaka T, Yokoo H, Nakanishi K, Kamiyama T, Todo S, Hirohashi S, Kondo T.

Hepatology. 2008 Dec;48(6):1851-63. doi: 10.1002/hep.22552.

PMID:
18937283

Supplemental Content

Support Center